Crescent Biopharma Reports Q1 2026 Results, Advances CR-001 and CR-003 Clinical Trials
CBIO has more than doubled off its 52-week low of $8.72.
Summary
Crescent Biopharma reported increased Q1 2026 net loss and cash burn, but confirmed the initiation of Phase 1/2 clinical trials for CR-001 and CR-003, with a cash runway of at least 12 months.
Key Events · Earnings and Guidance · CBIO
-
Q1 2026 Financial Performance
The company reported a net loss of $23.3 million for the three months ended March 31, 2026, an increase from $15.1 million in the prior-year period. Net cash used in operating activities was $8.9 million for the quarter.
-
Strong Cash Position and Runway
As of March 31, 2026, cash and cash equivalents stood at $189.2 million. Management expects this to fund operations for at least twelve months from the filing date (April 29, 2026), following a previously announced $185 million private placement in December 2025.
-
Clinical Trial Initiations for CR-001 and CR-003
Crescent Biopharma initiated a global Phase 1/2 clinical trial for CR-001 in February 2026 and a Phase 1/2 trial for CR-003 (SKB105) in China during Q1 2026 through its partner Kelun. Initial data for CR-001 is anticipated in Q1 2027.
-
Strategic Licensing Agreements
The company received $20.0 million upfront from Kelun for exclusive rights to CR-001 in Greater China and paid $80.0 million upfront to Kelun for exclusive rights to SKB105 (CR-003) outside Greater China. These transactions were previously announced in the 10-K.
Analysis · CBIO · Life Sciences
Crescent Biopharma's Q1 2026 report details increased operating losses and cash burn, which is typical for a clinical-stage biotechnology company actively advancing its pipeline. The company has successfully initiated Phase 1/2 clinical trials for its lead candidate CR-001 and for CR-003 (SKB105), demonstrating execution on its strategic development goals. The cash position, supported by a previously announced $185 million private placement, provides a runway of at least twelve months, mitigating immediate liquidity concerns. The sale of legacy intellectual property also adds a modest amount of non-dilutive capital. Investors should monitor the progress of these clinical trials and future financing needs.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CBIO was trading at $20.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $577M. The 52-week trading range was $8.72 to $28.77. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.